Barclays’s The Oncology Institute TOI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$46.6K Sell
15,176
-91,276
-86% -$280K ﹤0.01% 4345
2025
Q4
$379K Buy
106,452
+20,605
+24% +$76.4K ﹤0.01% 4010
2025
Q3
$300K Sell
85,847
-17,823
-17% -$61.1K ﹤0.01% 4102
2025
Q2
$213K Buy
+103,670
New +$259K ﹤0.01% 4233
2023
Q2
Sell
-19,840
Closed -$13.4K 5075
2023
Q1
$13.4K Buy
19,840
+10,497
+112% +$13.4K ﹤0.01% 4710
2022
Q4
$15.4K Buy
9,343
+7,868
+533% +$22.1K ﹤0.01% 4861
2022
Q3
$7K Buy
1,475
+534
+57% +$3.14K ﹤0.01% 4429
2022
Q2
$5K Buy
+941
New +$6.85K ﹤0.01% 4789

Other funds holding TOI

Barclays's TOI Position: Q1 2026 in Review

Barclays reduced its The Oncology Institute (TOI) stake by 86% in Q1 2026, selling an estimated $280K and leaving 15,176 shares worth $46.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4345.

Barclays first reported a position in TOI in Q2 2022 and has held it in 8 quarters since. The position peaked at $379K in Q4 2025. 115 funds tracked by Wall St. Rank hold TOI as of Q1 2026.

  • Barclays held 15,176 shares of The Oncology Institute worth $46.6K as of Q1 2026.
  • Barclays sold 91,276 The Oncology Institute shares in Q1 2026, an estimated $280K.
  • The Oncology Institute made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4345 holding.
  • Barclays first reported a position in The Oncology Institute in Q2 2022 and has held it in 8 quarters since.
  • Barclays's The Oncology Institute position peaked at $379K in Q4 2025.
  • 115 funds tracked by Wall St. Rank held The Oncology Institute as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.